Download Poster template - [email protected]

yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Cases of political abuse of psychiatry in the Soviet Union wikipedia, lookup

Separation anxiety disorder wikipedia, lookup

Mania wikipedia, lookup

Mental status examination wikipedia, lookup

Schizoaffective disorder wikipedia, lookup

Conduct disorder wikipedia, lookup

Generalized anxiety disorder wikipedia, lookup

History of psychiatric institutions wikipedia, lookup

Dissociative identity disorder wikipedia, lookup

Political abuse of psychiatry in Russia wikipedia, lookup

Narcissistic personality disorder wikipedia, lookup

Spectrum disorder wikipedia, lookup

Autism therapies wikipedia, lookup

Antisocial personality disorder wikipedia, lookup

Mental disorder wikipedia, lookup

Biology of depression wikipedia, lookup

Olanzapine wikipedia, lookup

Emergency psychiatry wikipedia, lookup

Causes of mental disorders wikipedia, lookup

Antipsychotic wikipedia, lookup

History of psychiatry wikipedia, lookup

Child psychopathology wikipedia, lookup

Abnormal psychology wikipedia, lookup

Autism spectrum wikipedia, lookup

Diagnostic and Statistical Manual of Mental Disorders wikipedia, lookup

Pyotr Gannushkin wikipedia, lookup

Asperger syndrome wikipedia, lookup

Classification of mental disorders wikipedia, lookup

History of mental disorders wikipedia, lookup

Controversy surrounding psychiatry wikipedia, lookup

Psychopharmacology wikipedia, lookup

The pharmacokinetics of Risperdal and its weight gaining side effects in adolescents
with irritability due to autism and disruptive behavior disorders
Chelsea M. Vink
Grand Valley State University, Allendale, Michigan 49401
Risperidone, known by the brand name of Risperdal, is an
atypical antipsychotic medication often prescribed to
adolescents in psychiatric facilities in order to treat their
irritability and aggression due to autism and disruptive
behavior disorders. One of the side effects associated with
Risperdal is an increase in weight gain. The combination of
a medication with a common side effect of weight gain, in
addition to a sedentary lifestyle due to being in a locked
facility, can lead to serious health concerns associated with
obesity including Type II Diabetes, high blood pressure, and
high cholesterol.
Risperdal works to decrease activity of serotonin and norepinephrine in the deep limbic system, as well as decrease activity of dopamine in the
cingulate gyrus.
Normal brain activity
Disruptive behavior
“Ring of Fire”
ASD engaging in eye contact
This project was done in order to discover if there’s a better
alternative to Risperdal consistent with the medication’s
positive outcomes but without the negative side effect of
weight gain.
Although Risperdal is associated with significant weight
gain in adolescents, other alternatives that are offered to
reduce agitation and irritability in adolescents with autism
and disruptive behavior disorders seem to be about equal, if
not larger, in the magnitude of weight gained as a side effect
of the medication (Table 2).
Since Risperdal is proven to be effective, adolescents
with autism and behavioral disorders will likely continue to
be prescribed Risperdal for their irritable and aggressive
symptoms. Since weight gain is a significant side effect,
there should be plans implemented for daily activity and
exercise for adolescents that take Risperdal and are patients
in a locked psychiatric facility in order to reduce risk of
serious health concerns associated with obesity such as Type
II Diabetes, high blood pressure, and high cholesterol.
Literature cited
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders: DSM-5. Washington, D.C: American
Psychiatric Association.
Baldessarini, R.J., Gardner, D.M., Waraich, P. (2005). Modern antipsychotic drugs: a clinical overview. Canadian Medical Association
Journal 172(13). 1703-11. Retrieved from PubMed.
The Cochrane Collaboration. (2012). Atypical antipsychotic drugs for disruptive behavior disorders in children and youths. In PubMed
Health. Retrieved from
Colpaert, F.C. (2003). Discovering risperidone: the LSD model of psychopathology. Nature Reviews. Drug Discovery 2(4). 315-20. Retrieved
from PubMed.
Dietrich, A., Dinnissen, M., Hoekstra, P.J., Van den Hoofdakker, B.J. (2015). Clinical and pharmacokinetic evaluation of risperidone for the
management of autism spectrum disorder. Expert Opinion on Drug Metabolism & Toxicology 11(1), 111-24. Retrieved from PubMed.
Eens, A., Gommeren, W., Janssen, P.A., Leysen, J.E., Stoof, J.C. (1988). Biochemical profile of Risperidone, a new antipsychotic. The
Journal of Pharmacology and Experimental Therapeutics 247(2). 661-70.
Günther, T., Herpertz-Dahlmann, B., Jolles, J., & Konrad, K. (2006). The influence of risperidone on attentional functions in children and
adolescents with attention Deficit/Hyperactivity disorder and co-morbid disruptive behavior disorder. Journal of Child and
Adolescent Psychopharmacology 16(6), 725-735. Retrieved from PsycINFO.
Miral, S., Gencer, O., Neslihan Inal-Emiroglu, F. (2008). Comparison of long-term efficacy and safety of risperidone and haloperidol in
children and adolescents with autistic disorder: an open label maintenance study. European Child and Adolescent Psychiatry 17(4).
217-25. Retrieved from PubMed.
Materials and methods
Electronic searches were performed in PubMed (1998 –
2015), PsycInfo (1993 – 2014), MEDLINE (1993 – 2014),
and WEBMD (2007). The main search strategy used
keywords for medications (risperidone OR atypical
antipsychotics OR medications OR prescriptions OR mood
stabilizers) and mood/mental disorders (aggression OR
irritability OR autism OR disruptive behavior disorders OR
conduct disorder OR oppositional defiant disorder OR
ADHD). In addition, psychiatric illnesses were researched
using the Diagnostic and Statistical Manual of Mental
Disorders (5th ed.: DSM-V; American Psychiatric
Association, 2013). An outline was created and constantly
updated in order to maintain cohesiveness of research.
As demonstrated in the single-photon emission computerized tomography (SPECT) scans above, brain activity of patients with disruptive behavior
disorders, autism, and ADHD tend to show over activation in the deep limbic system and cingulate gyrus.
Table 1. Target Receptors of Medications used to Treat Irritability
High Affinity
Moderate Affinity
Serotonin: 5-HT2A
Dopamine: D2
Adrenaline: α1, α2
Histamine: H1
Serotonin: 5-HT2A, 5-HT2C, 5HT6
Dopamine: D1, D2, D3, D4
Adrenaline: α1
Histamine: H1
Serotonin: 5-HT1A, 5-HT2
Dopamine: D1, D2
Adrenaline: α1, α2
Histamine: H1
Serotonin: 5-HT1A, 5-HT2A
Dopamine: D2, D3
Serotonin: 5-HT1A, 5-HT1C, 5-HT1D Dopamine: D1
Figure 1. Molecular
structure of risperidone
Serotonin: 5-HT2A, 5-HT2C, 5HT6, 5-HT7
Dopamine: D4
Adrenaline: α1A, α2A
Histamine: H1
Muscarinic: M1
Serotonin: 5-HT2
Dopamine: D2
Weak Affinity
Brain SPECT scans
Amen Clinics & Brain SPECT Imaging. (2012). Retrieved from
Nuclear Imaging of Brains. (2015). Retrieved from
Puckette, M. (2009). Defying ODD: What it is, and ways to manage. Retrieved from
Spanaugle, M. (2012). Anxiety. Retrieved from
Spect Scans. (2015). Retrieved from
Table 2. Average Weight Gain in Adolescents
Serotonin: 5-HT3
Muscarinic: M1, M2, M3, M4, M5
Serotonin: 5-HT2C, 5-HT7
Dopamine: D4
Adrenaline: α1
Histamine: H1
Serotonin: 5-HT1A, 5-HT3
Dopamine: D1, D2
Adrenaline: β1
Dopamine: D3, D5
Brand Name Average Weight Gain
0 – 4.4 kg
0.9 – 13.5 kg
Further information
2.3 – 6.1 kg
0 – 4.4 kg
0.9 – 9.5 kg
0 – 4.4 kg
More information on brain SPECT scanning can be found on
Amen Clinics’ website located at
Information on psychiatric illnesses such as ADHD,
ASD, oppositional defiant disorder, and conduct disorder can
be found in the Diagnostic and Statistical Manual of Mental
Disorders (5th ed.: DSM-V; American Psychiatric
Association, 2013).